This page is for education and does not replace medical advice. Dosing is individualized, and your prescriber and the FDA-approved labeling for your medicine come first. Dosing information reflects the FDA-approved labeling reviewed on November 14, 2026.
Tirzepatide never starts at the full dose. The first 4 weeks use 2.5 mg once weekly, a starting dose the FDA-approved label describes as being for treatment initiation, not for long-term maintenance.
Quick answer. The tirzepatide dosage chart starts at 2.5 mg once weekly for 4 weeks. After that, the dose can go up in 2.5 mg steps, no sooner than every 4 weeks, to a maximum of 15 mg weekly. The FDA-approved maintenance doses are 5 mg, 10 mg and 15 mg. Your prescriber chooses the dose based on how you respond and how well you tolerate it.
This chart applies to Zepbound, approved for chronic weight management and for obstructive sleep apnea in adults with obesity, and to Mounjaro, approved for type 2 diabetes. Both contain tirzepatide and follow the same dose steps. Your own schedule is set by your prescriber, so use this page to understand the steps, not to choose a dose.
This table shows the fastest schedule the FDA label allows for Zepbound. Each dose is taken once a week, and each step lasts at least 4 weeks. Your provider may hold a dose longer.
| Weeks | Weekly dose | Dose role (FDA label) |
| Weeks 1 to 4 | 2.5 mg | Starting dose for treatment initiation. Not a maintenance dose. |
| Weeks 5 to 8 | 5 mg | Escalation step. Also a maintenance dose. |
| Weeks 9 to 12 | 7.5 mg | Escalation step only. |
| Weeks 13 to 16 | 10 mg | Escalation step. Also a maintenance dose. |
| Weeks 17 to 20 | 12.5 mg | Escalation step only. |
| Week 21 and later | 15 mg | Maintenance dose and the maximum dose. |
Source: the FDA-approved Zepbound prescribing information on DailyMed.
For obstructive sleep apnea, the label lists 10 mg or 15 mg as the maintenance dose. The Mounjaro label uses the same steps for type 2 diabetes. Review the full label for the boxed warning and complete safety information.
The starting dose of tirzepatide is 2.5 mg injected under the skin once a week for 4 weeks. After 4 weeks, the dose goes to 5 mg. The 2.5 mg dose is not approved as a maintenance dose, so it is a first step, not a stopping point. Some people notice little change at 2.5 mg, and that fits the plan: this dose exists to help your body adjust.
For weight management, the label lists 5 mg, 10 mg and 15 mg once weekly as maintenance doses. The 7.5 mg and 12.5 mg doses are steps along the way. The label tells prescribers to consider treatment response and tolerability when choosing a maintenance dose, and to consider a lower one if a person does not tolerate it. Reaching 15 mg is not required.
Tirzepatide side effects are mostly digestive, such as nausea, and they are most likely to appear when treatment starts and after each dose increase. This is one reason the label spaces increases at least 4 weeks apart. In the label’s clinical trial data, severe stomach and intestinal reactions were reported more often at 10 mg and 15 mg than at 5 mg, so a higher dose is not automatically an easier one.
Between visits, keep track of:
Call your provider promptly about severe or lasting stomach pain, or vomiting that keeps you from drinking fluids. In an emergency, call 911.
The label sets a minimum of 4 weeks at each dose before an increase. That gives your digestive system time to adjust before the next step. Moving faster than your prescriber advises can raise the chance of nausea and vomiting, and can lead some people to stop treatment.
Weight does not move in a straight line. Water retention, hormonal cycles and the time of your last meal can shift the number on the scale from day to day. If a plateau lasts several weeks despite consistent use, a provider usually reviews a few things before deciding whether to go to the next dose step:
If everything checks out and you tolerate the current dose, the next step up may be the right move. At 15 mg there is no higher approved dose, so the review focuses on the other factors.
If nausea, vomiting or other digestive symptoms are significant, pushing through is not always the answer. Your provider may:
Never skip steps, change your dose or stop on your own. Call your prescriber first. Reaching a higher dose sooner is not the goal.
Both medicines raise the dose every 4 weeks. Semaglutide (Wegovy) reaches its usual 2.4 mg dose at week 17, while tirzepatide (Zepbound) reaches 15 mg at week 21 when every step is taken at the label’s fastest pace. The two are not interchangeable and should not be used together.
| Weeks | Wegovy injection (semaglutide) | Zepbound (tirzepatide) |
| Weeks 1 to 4 | 0.25 mg | 2.5 mg |
| Weeks 5 to 8 | 0.5 mg | 5 mg |
| Weeks 9 to 12 | 1 mg | 7.5 mg |
| Weeks 13 to 16 | 1.7 mg | 10 mg |
| Weeks 17 to 20 | 2.4 mg (recommended maintenance dose) | 12.5 mg |
| Week 21 and later | 2.4 mg (1.7 mg is an alternative maintenance dose) | 15 mg |
This table covers Wegovy injection. The Wegovy label also lists a 7.2 mg pen and tablets, and Ozempic, which is approved for type 2 diabetes, follows a different schedule. Source: the Wegovy label on DailyMed.
If you miss a weekly dose, take it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and take your next dose on your regular day. Do not take two doses at once to make up for a missed one.
Time since the missed dose | What to do |
4 days (96 hours) or less | Take it as soon as possible, then go back to your regular weekly day. |
More than 4 days | Skip it. Take your next dose on your regular day. |
More than one dose in a row | Call your provider before you restart. The right restart dose depends on how long the gap was and how you tolerated treatment. |
You can change the day of your weekly dose if at least 3 days (72 hours) pass between doses. Ask your provider before you change your schedule.
Zepbound comes as single-dose pens and single-dose vials, each holding one dose in 0.5 mL, in six strengths from 2.5 mg to 15 mg. It also comes as a multi-dose vial or a single-patient-use KwikPen that holds four doses. Each dose from a multi-dose vial or KwikPen is 0.6 mL, so the strength on the package is the total for four doses.
Package strength (per 2.4 mL) | Doses inside | Concentration | Each 0.6 mL dose |
10 mg | 4 | 4.17 mg per mL | 2.5 mg |
20 mg | 4 | 8.33 mg per mL | 5 mg |
30 mg | 4 | 12.5 mg per mL | 7.5 mg |
40 mg | 4 | 16.7 mg per mL | 10 mg |
50 mg | 4 | 20.8 mg per mL | 12.5 mg |
60 mg | 4 | 25 mg per mL | 15 mg |
Follow the instructions that come with your device. Do not combine or divide doses between packages unless your provider or pharmacist tells you to.
Syringes marked in units measure volume, not medicine strength. On a standard syringe that holds 100 units per mL, 20 units is 0.2 mL. How many milligrams are in 0.2 mL depends on the concentration of the vial, which is printed in mg per mL. The same number of units can mean very different milligram doses from different vials.
The relationship is milligrams = milliliters x concentration (mg per mL). For example, the label lists a 0.6 mL dose from the 25 mg per mL vial as 15 mg, and a 0.6 mL dose from the 4.17 mg per mL vial as 2.5 mg. This is here to show why a unit count alone is not enough. Do not work out your own dose. Ask your pharmacist or prescriber to write your dose in mg, mL and units on your instructions, and to check it against the label on your vial.
Option B: If your medicine was compounded, the concentration on your pharmacy label can differ from the FDA-approved products above, and compounded drugs are not FDA-approved. Ask your pharmacist to confirm the concentration before every refill.
At each follow-up, your provider at Windermere Medical Group reviews how you are tolerating the dose, your weight trend and the lab results your care plan calls for. Then they decide whether to move up, hold the dose or step back. Care is available in Cumming, Canton, Alpharetta, Lawrenceville, Baldwin, and Gainesville, and follow-up visits can also take place through our Virtual Clinic.
Dr. Priya Bayyapureddy, MD, is a board-certified internal medicine physician and a diplomate of the American Board of Obesity Medicine. She and the care team treat the dose as a decision made with you, based on how you are responding, not as a fixed calendar.
To see how this fits into a broader program, read about our medical weight loss and aesthetic services.
Once a dose is effective and well tolerated, treatment continues at that weekly dose, with follow-up visits and labs as your provider orders them. GLP-1 treatment is generally managed as a long-term therapy, so talk with your provider before lowering your dose or stopping. Our guide to GLP-1 weight loss treatment covers what to expect over time.
A tirzepatide dosage chart looks simple on paper: a straight line from 2.5 mg to 15 mg. In practice, the right pace depends entirely on how your body responds along the way, and that’s not something a fixed schedule can account for on its own. Regular follow-ups with a provider who’s actually watching your tolerability and progress, available at any Windermere Medical Group location in Georgia, make that adjustment possible in real time instead of guessing from a printed chart.
If you take one thing from this chart, let it be this: the number on the schedule is a guideline, not a deadline. Your body doesn’t know or care what month it is. It responds to how well it’s tolerating the current dose, how consistent your protein and hydration have been, and how much time it’s had to adjust. A provider paying attention to those signals, rather than a calendar alone, is what actually makes titration work the way it’s supposed to.
At the fastest pace the FDA label allows, it takes 20 weeks (about 5 months) to move from the first 2.5 mg dose to 15 mg, because each step lasts at least 4 weeks. Your provider may hold a dose longer, and you do not have to reach 15 mg.
The starting dose is 2.5 mg injected once a week for 4 weeks. It is meant for treatment initiation, not for long-term maintenance.
No. Reaching 15 mg is not required. The label tells prescribers to consider treatment response and tolerability when choosing a maintenance dose, and a lower maintenance dose may be appropriate. Your prescriber decides.
Take it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip it and take your next dose on your regular day. Do not take two doses at once. If you have missed more than one dose in a row, call your provider.
Yes. A prescriber can hold a dose longer or step back to the previous dose. Do not change your dose on your own. Call your prescriber first.
For weight management, the FDA label lists 5 mg, 10 mg and 15 mg once weekly as maintenance doses. The 7.5 mg and 12.5 mg doses are steps along the way. The maximum dose is 15 mg once weekly.
Once a week, on the same day each week, with or without food. If you need to change the day, keep at least 3 days (72 hours) between doses and ask your provider first.
The FDA label says using tirzepatide with other tirzepatide-containing products or with any GLP-1 receptor agonist, such as semaglutide, is not recommended. Talk to your provider before making any change.
Both contain tirzepatide and use the same dose steps. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes.
Units measure volume, not milligrams. On a syringe that holds 100 units per mL, 20 units is 0.2 mL. The milligrams in 0.2 mL depend on the concentration of your vial, so there is no single answer. Ask your pharmacist or prescriber to confirm your dose in writing.
Dr. Priya Bayyapureddy, MD is a board certified Internal Medicine doctor with over 20 years of experience in primary care Internal Medicine. Dr. Bayyapureddy completed her Internal Medicine residency at Emory University School of Medicine and internship at University of Tennessee College of Medicine at Chattanooga.
Recent Post